Astellas Pharma is focusing on diversification, with its portfolio spanning cancer, vision loss and menopause treatments. Its Chief Medical Officer, Tadaaki Taniguci, said the company was also expanding its gene therapy output, using acquisitions and licensing to build capability, while in oncology, the firm’s lead drugs include treatments for prostate and bladder cancer. Astellas is also testing a small molecule for treating menopause symptoms.
Warning issued over ‘fast flux’ techniques used to obscure malicious signals on compromised networks
Law enforcement agencies have warned that organizations face a common network vulnerability that allows hackers to dodge detection and distribute malicious software indiscriminately. Referred to
